Patents Assigned to Tiger Biotherapeutics Inc.
  • Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
    Patent number: 12195459
    Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.
    Type: Grant
    Filed: April 24, 2024
    Date of Patent: January 14, 2025
    Assignee: Tiger Biotherapeutics Inc.
    Inventors: Robert Luo, Ji Liu, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Glutarimide-containing KRAS-mutant degrader compounds and uses thereof
    Patent number: 12168058
    Abstract: The present disclosure relates to novel glutarimide-containing compounds with KRAS mutant form degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of diseases and conditions.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: December 17, 2024
    Assignee: Tiger Biotherapeutics, Inc.
    Inventors: Ji Liu, Robert Luo, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian
  • Glutarimide-containing pan-KRAS-mutant degrader compounds and uses thereof
    Patent number: 12110291
    Abstract: The present disclosure relates to novel pan-KRAS glutarimide-containing compounds with KRAS degradation activities, pharmaceutical compositions containing such compounds, and their use in prevention and treatment diseases and conditions.
    Type: Grant
    Filed: November 30, 2023
    Date of Patent: October 8, 2024
    Assignee: Tiger Biotherapeutics Inc.
    Inventors: Robert Luo, Ji Liu, Pin Huang, Jie Su, Yan Feng, Ke Liu, Jie Fan, Wei He, Yimin Qian